WallStreetZenWallStreetZen

NASDAQ: XRTX
Xortx Therapeutics Inc Stock

Open Broker Account
$1.21+0.27 (+28.72%)
Updated Sep 23, 2022
XRTX Price
$1.21
Fair Value Price
N/A
Market Cap
$15.72M
52 Week Low
$0.90
52 Week High
$5.89
P/E
-6.24x
P/B
1.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.31M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.31
Operating Cash Flow
-$7M
Beta
0.01
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XRTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XRTX is good value based on its book value relative to its share price (1.66x), compared to the US Biotechnology industry average (4.31x)
P/B vs Industry Valuation
XRTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XRTX due diligence checks available for Premium users.

Be the first to know about important XRTX news, forecast changes, insider trades & much more!

XRTX News

Valuation

XRTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.24x
Industry
15.88x
Market
27.65x

XRTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.66x
Industry
4.31x
XRTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XRTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.2M
Profit Margin
0%
XRTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$12.4M
Liabilities
$2.9M
Debt to equity
0.31
XRTX's short-term assets ($10.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XRTX's short-term assets ($10.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.9M
Investing
-$21.5k
Financing
-$6.1k
XRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XRTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XRTX$15.72M+29.27%-6.24x1.66x
SGTX$15.71M-7.09%-0.24x0.30x
OTIC$15.73M-5.15%-0.35x0.49x
APVO$15.88M-5.17%2.35x0.69x
TTNP$15.51M-6.19%-1.22x2.74x

Xortx Therapeutics Stock FAQ

What is Xortx Therapeutics's quote symbol?

NASDAQ: XRTX) Xortx Therapeutics trades on the NASDAQ under the ticker symbol XRTX. Xortx Therapeutics stock quotes can also be displayed as NASDAQ: XRTX.

If you're new to stock investing, here's how to buy Xortx Therapeutics stock.

What is the 52 week high and low for Xortx Therapeutics (NASDAQ: XRTX)?

(NASDAQ: XRTX) Xortx Therapeutics's 52-week high was $5.89, and its 52-week low was $0.90. It is currently -79.46% from its 52-week high and 35.2% from its 52-week low.

How much is Xortx Therapeutics's stock price per share?

(NASDAQ: XRTX) Xortx Therapeutics stock price per share is $1.21 today (as of Sep 23, 2022).

What is Xortx Therapeutics's Market Cap?

(NASDAQ: XRTX) Xortx Therapeutics's market cap is $15.72M, as of Sep 27, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xortx Therapeutics's market cap is calculated by multiplying XRTX's current stock price of $1.21 by XRTX's total outstanding shares of 12,989,687.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.